|
WO2020247547A1
|
|
Cancer vaccine compositions and methods for use thereof
|
|
US2020282036A1
|
|
Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria
|
|
WO2019040846A1
|
|
Immuno-oncology compositions and methods for use therof
|
|
US2020171141A1
|
|
Compositions and Methods for Generating an Immune Response to LASV
|
|
CA3026054A1
|
|
Compositions and methods for generating an immune response to hepatitis b virus
|
|
EP3416978A1
|
|
Multivalent hiv vaccine boost compositions and methods of use
|
|
US2019030157A1
|
|
Compositions and Methods for Generating an Immune Response to a Flavivirus
|
|
AU2017206102A1
|
|
Compositions and methods for generating an immune response to a tumor associated antigen
|
|
WO2016115116A1
|
|
Compositions and methods for generating an immune response to a hemorrhagic fever virus
|
|
WO2016068919A1
|
|
Combination therapy for treating viral reservoirs
|
|
US2013280215A1
|
|
Mva vectors expressing polypeptides and having high level production in certain cell lines
|
|
AP201206258A0
|
|
Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
|
